

# **Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®\* in chronic myeloid leukemia trial**

Dec 08, 2020

---

**Source URL:** <https://qa1.novartis.us/us-en/news/media-releases/novartis-investigational-stamp-inhibitor-asciminib-abl001-shows-superior-mmr-rate-bosulif-chronic-myeloid-leukemia-trial-0>

## **List of links present in page**

1. <https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-investigational-stamp-inhibitor-asciminib-abl001-shows-superior-mmr-rate-bosulif-chronic-myeloid-leukemia-trial-0>